Amplia secures funding to assess AMP945 topical applications
News release
by
Amplia Therapeutics Ltd
Melbourne, Victoria
|
May 22, 2023 02:00 PM Eastern Daylight Time
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns tells Proactive the company has received grant funding to undertake a research collaboration with Australia’s national science agency to develop topical formulations of its FAK inhibitors. Amplia will work with researchers at CSIRO to help develop formulations that could be applied topically to wounds and burns to aid healing and reduce scarring.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
